Effect and risk factors of pitavastatin on high sensitivity C-reactive protein in patients with hypercholesterolemia: a multilevel models analysis
To evaluate the effect of pitavastatin on high sensitivity C-reactive protein (hsCRP) in patients with hypercholesterolemia, and determine risk factors for the effect. This study was a 12-week, multicenter, open-label, without parallel-group comparison, phase IV clinical trail. There were 330 subjec...
Gespeichert in:
| Veröffentlicht in: | Zhong hua yi xue za zhi 2012-06, Vol.92 (24), p.1681-1685 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | chi |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1685 |
|---|---|
| container_issue | 24 |
| container_start_page | 1681 |
| container_title | Zhong hua yi xue za zhi |
| container_volume | 92 |
| creator | Mao, Yong Yu, Jin-ming Zhan, Yi-qiang Hu, Da-yi Ding, Rong-jing Zhang, Fen Li, She-chang Kong, Qun-yu Lin, Fan-li Jia, Gong-xian |
| description | To evaluate the effect of pitavastatin on high sensitivity C-reactive protein (hsCRP) in patients with hypercholesterolemia, and determine risk factors for the effect.
This study was a 12-week, multicenter, open-label, without parallel-group comparison, phase IV clinical trail.
There were 330 subjects in the per protocol set. Contrast to the baseline, the average levels of hsCRP in all of subjects and the group without a history of receiving previous statin medication at week 12 post-treatment decreased respectively 26.4% (1.20 mg/L vs 1.68 mg/L) and 27.5% (1.21 mg/L vs 1.97 mg/L, all P < 0.05). The results of multilevel models indicated that the average levels of hsCRP reduced with the passage of treatment time, the time-varying rate of per-visit was 0.97 mg/L (95% confidence interval 0.96 - 0.98). Controlled individual background covariates, the model predicted that pulse pressure and white blood cell count on the baseline had the significant positive effects on hsCRP (P < 0.01).
Pitavastatin decreases hsCR |
| doi_str_mv | 10.3760/cma.j.issn.0376-2491.2012.24.007 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1038067790</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1038067790</sourcerecordid><originalsourceid>FETCH-LOGICAL-p126t-5d22feb1e9d819b630ac7611664c36ff7aa0c09e85154faa0893975760ee7e383</originalsourceid><addsrcrecordid>eNo9kMtqwzAURLVoaUKaXyhaZmNXD9uyuishfUCgm3ZtZPuqVis_6quk5Df6xRX0AReGOxyGYQjZcJZKVbDrpjfpW-oQh5RFIxGZ5qlgXKQiSxlTZ2T57y_IGtHVLFNSCyb4BVkIobOM5-WSfO2shSZQM7R0dvhOrWnCOCMdLZ1cMEeDwQQ30HGgnXvtKMKALrijCye6TWaIuDsCneYxQMTiTZGHISD9dKGj3WmCuelGDxhgjtI7c0MN7Q8-OA9H8LQfW_AYKxh_QoeX5Nwaj7D-1RV5uds9bx-S_dP94_Z2n0xcFCHJWyEs1Bx0W3JdF5KZRhWcF0XWyMJaZQxrmIYy53lm41NqqVUe1wNQIEu5Ipuf3Nj94xDrVb3DBrw3A4wHrDiTJSuU0iyiV7_ooe6hrabZ9WY-VX87ym9jiXvy</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1038067790</pqid></control><display><type>article</type><title>Effect and risk factors of pitavastatin on high sensitivity C-reactive protein in patients with hypercholesterolemia: a multilevel models analysis</title><source>MEDLINE</source><source>Free E-Journal (出版社公開部分のみ）</source><creator>Mao, Yong ; Yu, Jin-ming ; Zhan, Yi-qiang ; Hu, Da-yi ; Ding, Rong-jing ; Zhang, Fen ; Li, She-chang ; Kong, Qun-yu ; Lin, Fan-li ; Jia, Gong-xian</creator><creatorcontrib>Mao, Yong ; Yu, Jin-ming ; Zhan, Yi-qiang ; Hu, Da-yi ; Ding, Rong-jing ; Zhang, Fen ; Li, She-chang ; Kong, Qun-yu ; Lin, Fan-li ; Jia, Gong-xian</creatorcontrib><description>To evaluate the effect of pitavastatin on high sensitivity C-reactive protein (hsCRP) in patients with hypercholesterolemia, and determine risk factors for the effect.
This study was a 12-week, multicenter, open-label, without parallel-group comparison, phase IV clinical trail.
There were 330 subjects in the per protocol set. Contrast to the baseline, the average levels of hsCRP in all of subjects and the group without a history of receiving previous statin medication at week 12 post-treatment decreased respectively 26.4% (1.20 mg/L vs 1.68 mg/L) and 27.5% (1.21 mg/L vs 1.97 mg/L, all P < 0.05). The results of multilevel models indicated that the average levels of hsCRP reduced with the passage of treatment time, the time-varying rate of per-visit was 0.97 mg/L (95% confidence interval 0.96 - 0.98). Controlled individual background covariates, the model predicted that pulse pressure and white blood cell count on the baseline had the significant positive effects on hsCRP (P < 0.01).
Pitavastatin decreases hsCR</description><identifier>ISSN: 0376-2491</identifier><identifier>DOI: 10.3760/cma.j.issn.0376-2491.2012.24.007</identifier><identifier>PMID: 22944158</identifier><language>chi</language><publisher>China</publisher><subject>Adult ; Aged ; C-Reactive Protein - metabolism ; Cholesterol, HDL - blood ; Cholesterol, LDL - blood ; Female ; Humans ; Hypercholesterolemia - blood ; Hypercholesterolemia - drug therapy ; Male ; Middle Aged ; Quinolines - pharmacology ; Quinolines - therapeutic use ; Risk Factors</subject><ispartof>Zhong hua yi xue za zhi, 2012-06, Vol.92 (24), p.1681-1685</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22944158$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mao, Yong</creatorcontrib><creatorcontrib>Yu, Jin-ming</creatorcontrib><creatorcontrib>Zhan, Yi-qiang</creatorcontrib><creatorcontrib>Hu, Da-yi</creatorcontrib><creatorcontrib>Ding, Rong-jing</creatorcontrib><creatorcontrib>Zhang, Fen</creatorcontrib><creatorcontrib>Li, She-chang</creatorcontrib><creatorcontrib>Kong, Qun-yu</creatorcontrib><creatorcontrib>Lin, Fan-li</creatorcontrib><creatorcontrib>Jia, Gong-xian</creatorcontrib><title>Effect and risk factors of pitavastatin on high sensitivity C-reactive protein in patients with hypercholesterolemia: a multilevel models analysis</title><title>Zhong hua yi xue za zhi</title><addtitle>Zhonghua Yi Xue Za Zhi</addtitle><description>To evaluate the effect of pitavastatin on high sensitivity C-reactive protein (hsCRP) in patients with hypercholesterolemia, and determine risk factors for the effect.
This study was a 12-week, multicenter, open-label, without parallel-group comparison, phase IV clinical trail.
There were 330 subjects in the per protocol set. Contrast to the baseline, the average levels of hsCRP in all of subjects and the group without a history of receiving previous statin medication at week 12 post-treatment decreased respectively 26.4% (1.20 mg/L vs 1.68 mg/L) and 27.5% (1.21 mg/L vs 1.97 mg/L, all P < 0.05). The results of multilevel models indicated that the average levels of hsCRP reduced with the passage of treatment time, the time-varying rate of per-visit was 0.97 mg/L (95% confidence interval 0.96 - 0.98). Controlled individual background covariates, the model predicted that pulse pressure and white blood cell count on the baseline had the significant positive effects on hsCRP (P < 0.01).
Pitavastatin decreases hsCR</description><subject>Adult</subject><subject>Aged</subject><subject>C-Reactive Protein - metabolism</subject><subject>Cholesterol, HDL - blood</subject><subject>Cholesterol, LDL - blood</subject><subject>Female</subject><subject>Humans</subject><subject>Hypercholesterolemia - blood</subject><subject>Hypercholesterolemia - drug therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Quinolines - pharmacology</subject><subject>Quinolines - therapeutic use</subject><subject>Risk Factors</subject><issn>0376-2491</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kMtqwzAURLVoaUKaXyhaZmNXD9uyuishfUCgm3ZtZPuqVis_6quk5Df6xRX0AReGOxyGYQjZcJZKVbDrpjfpW-oQh5RFIxGZ5qlgXKQiSxlTZ2T57y_IGtHVLFNSCyb4BVkIobOM5-WSfO2shSZQM7R0dvhOrWnCOCMdLZ1cMEeDwQQ30HGgnXvtKMKALrijCye6TWaIuDsCneYxQMTiTZGHISD9dKGj3WmCuelGDxhgjtI7c0MN7Q8-OA9H8LQfW_AYKxh_QoeX5Nwaj7D-1RV5uds9bx-S_dP94_Z2n0xcFCHJWyEs1Bx0W3JdF5KZRhWcF0XWyMJaZQxrmIYy53lm41NqqVUe1wNQIEu5Ipuf3Nj94xDrVb3DBrw3A4wHrDiTJSuU0iyiV7_ooe6hrabZ9WY-VX87ym9jiXvy</recordid><startdate>20120626</startdate><enddate>20120626</enddate><creator>Mao, Yong</creator><creator>Yu, Jin-ming</creator><creator>Zhan, Yi-qiang</creator><creator>Hu, Da-yi</creator><creator>Ding, Rong-jing</creator><creator>Zhang, Fen</creator><creator>Li, She-chang</creator><creator>Kong, Qun-yu</creator><creator>Lin, Fan-li</creator><creator>Jia, Gong-xian</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20120626</creationdate><title>Effect and risk factors of pitavastatin on high sensitivity C-reactive protein in patients with hypercholesterolemia: a multilevel models analysis</title><author>Mao, Yong ; Yu, Jin-ming ; Zhan, Yi-qiang ; Hu, Da-yi ; Ding, Rong-jing ; Zhang, Fen ; Li, She-chang ; Kong, Qun-yu ; Lin, Fan-li ; Jia, Gong-xian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p126t-5d22feb1e9d819b630ac7611664c36ff7aa0c09e85154faa0893975760ee7e383</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>chi</language><creationdate>2012</creationdate><topic>Adult</topic><topic>Aged</topic><topic>C-Reactive Protein - metabolism</topic><topic>Cholesterol, HDL - blood</topic><topic>Cholesterol, LDL - blood</topic><topic>Female</topic><topic>Humans</topic><topic>Hypercholesterolemia - blood</topic><topic>Hypercholesterolemia - drug therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Quinolines - pharmacology</topic><topic>Quinolines - therapeutic use</topic><topic>Risk Factors</topic><toplevel>online_resources</toplevel><creatorcontrib>Mao, Yong</creatorcontrib><creatorcontrib>Yu, Jin-ming</creatorcontrib><creatorcontrib>Zhan, Yi-qiang</creatorcontrib><creatorcontrib>Hu, Da-yi</creatorcontrib><creatorcontrib>Ding, Rong-jing</creatorcontrib><creatorcontrib>Zhang, Fen</creatorcontrib><creatorcontrib>Li, She-chang</creatorcontrib><creatorcontrib>Kong, Qun-yu</creatorcontrib><creatorcontrib>Lin, Fan-li</creatorcontrib><creatorcontrib>Jia, Gong-xian</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Zhong hua yi xue za zhi</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mao, Yong</au><au>Yu, Jin-ming</au><au>Zhan, Yi-qiang</au><au>Hu, Da-yi</au><au>Ding, Rong-jing</au><au>Zhang, Fen</au><au>Li, She-chang</au><au>Kong, Qun-yu</au><au>Lin, Fan-li</au><au>Jia, Gong-xian</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect and risk factors of pitavastatin on high sensitivity C-reactive protein in patients with hypercholesterolemia: a multilevel models analysis</atitle><jtitle>Zhong hua yi xue za zhi</jtitle><addtitle>Zhonghua Yi Xue Za Zhi</addtitle><date>2012-06-26</date><risdate>2012</risdate><volume>92</volume><issue>24</issue><spage>1681</spage><epage>1685</epage><pages>1681-1685</pages><issn>0376-2491</issn><abstract>To evaluate the effect of pitavastatin on high sensitivity C-reactive protein (hsCRP) in patients with hypercholesterolemia, and determine risk factors for the effect.
This study was a 12-week, multicenter, open-label, without parallel-group comparison, phase IV clinical trail.
There were 330 subjects in the per protocol set. Contrast to the baseline, the average levels of hsCRP in all of subjects and the group without a history of receiving previous statin medication at week 12 post-treatment decreased respectively 26.4% (1.20 mg/L vs 1.68 mg/L) and 27.5% (1.21 mg/L vs 1.97 mg/L, all P < 0.05). The results of multilevel models indicated that the average levels of hsCRP reduced with the passage of treatment time, the time-varying rate of per-visit was 0.97 mg/L (95% confidence interval 0.96 - 0.98). Controlled individual background covariates, the model predicted that pulse pressure and white blood cell count on the baseline had the significant positive effects on hsCRP (P < 0.01).
Pitavastatin decreases hsCR</abstract><cop>China</cop><pmid>22944158</pmid><doi>10.3760/cma.j.issn.0376-2491.2012.24.007</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0376-2491 |
| ispartof | Zhong hua yi xue za zhi, 2012-06, Vol.92 (24), p.1681-1685 |
| issn | 0376-2491 |
| language | chi |
| recordid | cdi_proquest_miscellaneous_1038067790 |
| source | MEDLINE; Free E-Journal (出版社公開部分のみ） |
| subjects | Adult Aged C-Reactive Protein - metabolism Cholesterol, HDL - blood Cholesterol, LDL - blood Female Humans Hypercholesterolemia - blood Hypercholesterolemia - drug therapy Male Middle Aged Quinolines - pharmacology Quinolines - therapeutic use Risk Factors |
| title | Effect and risk factors of pitavastatin on high sensitivity C-reactive protein in patients with hypercholesterolemia: a multilevel models analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T08%3A41%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20and%20risk%20factors%20of%20pitavastatin%20on%20high%20sensitivity%20C-reactive%20protein%20in%20patients%20with%20hypercholesterolemia:%20a%20multilevel%20models%20analysis&rft.jtitle=Zhong%20hua%20yi%20xue%20za%20zhi&rft.au=Mao,%20Yong&rft.date=2012-06-26&rft.volume=92&rft.issue=24&rft.spage=1681&rft.epage=1685&rft.pages=1681-1685&rft.issn=0376-2491&rft_id=info:doi/10.3760/cma.j.issn.0376-2491.2012.24.007&rft_dat=%3Cproquest_pubme%3E1038067790%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1038067790&rft_id=info:pmid/22944158&rfr_iscdi=true |